| Předmět: |
|
| Zdroj: |
Gene Therapy Weekly; 1/8/2024, p1826-1826, 1p |
| Abstrakt: |
Researchers from Xiamen University have developed a glycoengineered therapeutic antibody, huE6F6-fuc-, that shows promise in clearing hepatitis B surface antigen (HBsAg) in patients with chronic HBV infection. The antibody was found to have desirable physicochemical properties and demonstrated stronger viral clearance in vivo compared to the original antibody. The study suggests that huE6F6-fuc- could be a promising treatment for chronic HBV infection and provides guidance for antibody engineering in other disease fields. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
